EMD Serono, Inc., a subsidiary of Merck KGaA, has received FDA approval for the Gonal-f RFF Redi-ject (follitropin alfa injection), a disposable pre-filled drug injector pen intended for the subcutaneous injection of a liquid formulation of Gonal-f RFF. Gonal-f RFF Redi-ject is indicated for induction of ovulation and pregnancy in oligo-anovulatory women in whom the cause of infertility is functional and not due to primary ovarian failure, development of multiple follicles in ovulatory women as...